The AMP-activated protein kinase (AMPK) is a key regulator of cellular and whole-body energy homeostasis, which acts to restore energy homoeostasis whenever cellular energy charge is depleted. Over the last 2 decades, it has become apparent that AMPK regulates several other cellular functions and has specific roles in cardiovascular tissues, acting to regulate cardiac metabolism and contractile function, as well as promoting anticontractile, anti-inflammatory, and antiatherogenic actions in blood vessels. In this review, we discuss the role of AMPK in the cardiovascular system, including the molecular basis of mutations in AMPK that alter cardiac physiology and the proposed mechanisms by which AMPK regulates vascular function under physiological and pathophysiological conditions. (Circ Res.
T he AMP-activated protein kinase (AMPK) is the central component of a signaling pathway that regulates the switch between anabolism and catabolism, as well as many other aspects of cell function. [1] [2] [3] In this review, we focus on the physiological roles of AMPK within the cardiovascular system, although we start by discussing general features that apply in all mammalian cell types. Readers are also referred to 2 other recent reviews of the role of AMPK in cardiovascular disease. 4, 5 
Structure and Regulation of AMPK

Occurrence of Subunit Isoforms
AMPK exists universally as heterotrimeric complexes containing catalytic α subunits and regulatory β and γ subunits, which occur as multiple isoforms (α1/α2; β1/β2; γ1/γ2/γ3) encoded by distinct genes. These could give rise in principle to 12 heterotrimeric combinations, although specific combinations seem to be favored in specific cell types. For example, although skeletal muscle expresses mRNAs encoding all 7 subunit isoforms, assays of immunoprecipitated isoforms suggest that AMPK activity in human skeletal muscle is accounted for by just 3 combinations: α1β2γ1, α2β2γ1, and α2β2γ3. 6 The domain organization of the 7 AMPK subunit isoforms are shown in Figure 1 , and a representation of a crystal structure for the human α1β2γ1 heterotrimer 8 is shown in Figure 2 . Similar structures of the α2β1γ1 9 and α1β1γ1 10 complexes are available.
The α Subunits
The α subunits contain a kinase domain (α-KD) at their N-termini, with the small N-lobe (yellow in Figures 1 and 2 ) and larger C-lobe (green) typical of all protein kinases. The substrate Mg.ATP 2− binds in a deep cleft between these lobes, occupied in the structure in Figure 2 by the nonspecific kinase inhibitor staurosporine. Isolated α-KDs are only significantly active after phosphorylation by upstream kinases at a conserved threonine, usually referred to as Thr172. Thr172 phosphorylation is a good marker for AMPK activity, and Western blotting using phosphospecific antibodies against this site is often used as a semiquantitative measure of AMPK activity. However, this ignores the effects of allosteric activation of AMPK, a problem that can be overcome by also addressing the phosphorylation state of a downstream target, such as acetyl-CoA carboxylase (ACC). The α-KD is followed by a small globular domain termed the autoinhibitory domain (AID, orange) that, when AMP is not bound to the γ subunit, binds to both the N-and C-lobes of the KD and, thus, causes inhibition. 8 The AID is connected to the C-terminal domain (α-CTD, red) by the α-linker (blue), a region of extended polypeptide that interacts with the γ subunit when AMP is bound at site 3 (as is the case in Figure 2 ), thus, pulling the AID away from this inhibitory position.
The β Subunits
Two well-conserved regions within the β subunits are the CTD (β-CTD, silver-grey), which forms the core of the heterotrimeric complex, and the central carbohydrate-binding module (β-CBM, silver-blue). The β-CBM is related to carbohydratebinding domains usually occurring in enzymes that metabolize starch or glycogen, which localize those enzymes on their polysaccharide substrate. Consistent with this, the β-CBM causes a proportion of AMPK in cells to bind to the surface of glycogen particles. [11] [12] [13] In all 3 structures of mammalian heterotrimers, the β-CBM interacts with the N-lobe of the α subunit KD, with
Identity of Upstream Kinases
Identifying the upstream kinases that phosphorylate Thr172 was a difficult challenge, eventually solved by genome-wide biochemical screens that identified 3 upstream kinases in budding yeast. 21, 22 The mammalian kinases with catalytic domains most closely related to these were LKB1 (liver kinase B1) and the Ca 2+ /calmodulin-dependent kinase CaMKK2 (calmodulinactivated kinase kinase-2, also known as CaMKKβ), and evidence was soon obtained that both could act as physiological upstream kinases in mammalian cells. [23] [24] [25] [26] [27] [28] The discovery that LKB1 was an upstream kinase for AMPK was particularly interesting because LKB1 had previously been identified to be a tumor suppressor. 29 Phosphorylation of Thr172 by CaMKK2 [26] [27] [28] represents a mechanism by which hormones that increase cytosolic Ca 2+ can activate AMPK in the absence of energy stress.
General Features of AMPK Regulation Regulation by the Canonical Energy Stress Mechanism
It might be expected that a system that monitors cellular energy status would sense ATP and ADP, but interestingly, all metabolic enzymes known to directly monitor cellular energy charge (glycogen phosphorylase, 6-phosphofructo-1-kinase, fructose-1,6-bisphosphatase) primarily sense AMP and ATP, as does AMPK. The principal source of AMP in cells is thought to be the adenylate kinase reaction (2ADP↔ATP+AMP), which seems to operate close to equilibrium in most cells so that the AMP:ATP ratio will vary as the square of the ADP:ATP ratio. 30 The former is, therefore, a more sensitive indicator of falling energy status than the latter.
Binding of AMP activates AMPK by 3 complementary mechanisms, of which the first 2 are mimicked by ADP at higher concentration, while all 3 are antagonized by ATP: (1) inhibition of Thr172 dephosphorylation by protein phosphatases; (2) promotion of Thr172 phosphorylation by LKB1; and (3) allosteric activation. 31, 32 The structural model shown in Figure 2 suggests a mechanism, for which there is now supporting evidence, 8 to explain mechanisms (1) and (3). When AMP is bound at site 3, the αlinker interacts with the surface of the γ subunit containing that site ( Figure 2) . 8, 33 AMPK heterotrimers contain 2 rather distinct regions, the catalytic module (β-CBM, KD, AID; top/ front section in Figure 2 ) and the nucleotide-binding module (γ subunit, β-CTD, α-CTD; bottom/rear section in Figure 2 ). The hinge connecting them is the α linker, and release of the α linker on binding of ATP rather than AMP at site 3 is envisaged to allow the 2 modules to move apart, causing the AID to rotate back into its inhibitory position behind the α-KD. This conformational change would also increase accessibility of Thr172 to protein phosphatases, which in the AMP-bound conformation of Figure 2 is around the back, located in a deep cleft between the 2 modules. This model, therefore, explains not only how AMP binding at site 3 causes allosteric activation, but also why it protects against Thr172 dephosphorylation, with binding of ATP antagonizing both effects.
Multiple Mechanisms of Pharmacological Activation of AMPK
A selection of compounds commonly used to activate AMPK experimentally are listed in Table 1 . Those in class 1, including the antidiabetic drug metformin and berberine (derived Figure 2 . Structure of human AMP-activated protein kinase (AMPK; α1β2γ1 complex). 8 The model was created in spacefilling mode using PyMol v1.7.4.2 with the co-ordinates in PDB file 4RER and with color coding similar to that in Figure 1 . The heterotrimer was crystallized in the presence of β-cyclodextrin, which occupies the glycogen-binding site, staurosporine, which occupies the active site, and AMP, which occupies sites 1, 3, and 4 on the γ subunit (sites 1 and 4 are round the back in this view). Although Thr172 was phosphorylated, it is not visible in this view but lies in the cleft between the kinase domain C lobe and the β-CTD, just over the right-hand shoulder of the C-lobe. ADaM indicates Allosteric Drug and Metabolite; AID, autoinhibitory domain; CBM, carbohydrate-binding module; CBS1, cystathionine beta-synthase motif-1, etc; CTD, C-terminal domain; and NTD, N-terminal domain. Figure 3 . Two views of the structure of the 4 CBS repeats of the γ1 subunit. The model used the co-ordinates in PDB file 2V8Q 19 and was rendered in PyMol v1.7.4.2 with the γ 1 subunit in cartoon view. The 2 views are rotated 180° around the x axis (dashed line) with respect to each other, with the orientation of the top view being similar to that in Figure 2 . Note the pseudosymmetrical layout of the 4 CBS repeats, which are colored differently (and differently to Figures 1 and 2 ). Residues equivalent to those mutated in γ2 are highlighted using the dots version of space-filling representation and are numbered using the human γ2 numbering. The 3 molecules of bound AMP are labeled and are shown in standard space-filling view, with C atoms green; O, red; and N, blue.
from traditional Chinese medicine), inhibit complex I of the mitochondrial respiratory chain, while those in class 2, including 2-deoxyglucose, inhibit glycolysis. Both classes activate AMPK indirectly by increasing cellular AMP:ATP ratios. 34 These compounds are frequently used to activate AMPK experimentally, and studies using them are described later in this review. However, because they work by depleting cellular ATP, they should not be regarded as specific AMPK activators, and any results obtained with them should ideally be followed up using genetic approaches, such as the use of AMPK knockouts.
The third class of activator includes the widely used compound 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), a nucleoside that is taken up into cells and converted to the equivalent nucleotide, ZMP. An important caveat here is that although ZMP is an AMP analog that mimics the effects of AMP to activate AMPK, it is ≈50-fold less potent than AMP itself. 35 Because ZMP accumulates to millimolar concentrations inside cells, AICAR does cause AMPK activation, but ZMP also has off-target effects. For example, it is known to mimic the effects of AMP on phosphorylase 42 and fructose-1,6-bisphosphatase, 43 as well as AMPK. Another problem with AICAR is that it is an adenosine analogue, and although it does not seem to bind directly to adenosine receptors, in incubated cell systems it competes with endogenous adenosine for reuptake into cells by adenosine transporters, and so can have adenosine-like effects. 44 A more specific activator that works via a related mechanism (class 4) is C13, which is taken up by cells and converted by cellular esterases to the AMP analog C2, a potent AMPK activator, 36 although only for α1-and not α2-containing complexes. 45 Despite its selectivity for the α1 isoform, C2 binds to the γ subunit. Although the AMP and C2 binding sites overlap, they are not identical. 37 The other molecules of choice for selective activation of AMPK are those binding at the Allosteric Drug and Metabolite site located between the β-CBM and the N-lobe on the α subunit, such as A769662 and 991 (class 5). 9 All compounds binding this site are more potent activators of complexes containing AMPK-β1 rather than β2, and most are essentially β1-selective (Table 1 ). Using AMPK phosphorylated on Thr172, these activators cause a modest degree of allosteric activation (≤4-fold) and, by inhibiting dephosphorylation, also promote net Thr172 phosphorylation. 46, 47 More remarkably, they cause a much larger allosteric activation (≤65-fold) of AMPK that is not phosphorylated on Thr172, and this effect is synergistic with AMP. 48 At present, almost all of the activators known to bind at this site are synthetic compounds derived from highthroughput screens, although there is much speculation in the field that there is a naturally occurring ligand and, hence, the appearance of metabolite in its name. 16 However, no natural ligands occurring in animal cells that bind the Allosteric Drug and Metabolite site have yet been found. Salicylate, the natural plant product from which acetyl salicylic acid (aspirin) was derived, does activate AMPK by binding this site. 10, 41 It should also be noted that there are currently no specific pharmacological inhibitors of AMPK; compound C (dorsomorphin) is sometimes claimed to be a specific inhibitor, but this is not the case.
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Targets and Pathways Downstream of AMPK Catabolic Effects Switched on by AMPK
Once activated by energy stress, AMPK switches on catabolic pathways generating ATP, while switching off anabolic pathways and other processes consuming ATP, thus, acting to restore energy homeostasis. This topic has been discussed in more detail in previous reviews. [1] [2] [3] Examples of catabolic processes acutely switched on include cellular glucose uptake mediated by GLUT1 and GLUT4 (glucose transporters-1 and -4). Activation of GLUT1 may occur via phosphorylation of the thioredoxin interacting protein TXNIP, 50 while enhanced GLUT4 translocation to the plasma membrane in muscle seems to occur, at least in part, by phosphorylation of TBC1D1, which modulates trafficking of GLUT4-containing vesicles. 51 AMPK activation also enhances GLUT4 expression, 52 in part via phosphorylation of histone deacetylase-5 (HDAC5), promoting binding of 14-3-3 proteins and consequent retention of HDAC5, a transcriptional inhibitor, in the cytoplasm. 53, 54 AMPK can also cause a short-term activation of glycolysis via phosphorylation of PFKFB2 55 and PFKFB3, 56 isoforms of the bifunctional enzyme (6-phosphofructo-2-kinase: fructose-2,6-bisphosphatase) that synthesizes and breaks down fructose-2,6-bisphosphate, a key allosteric activator of 6-phosphofructo-1-kinase and, hence, glycolysis. PFKFB2 is expressed in the heart, while PFKFB3 occurs as an inducible form whose expression in monocytes and macrophages is induced by inflammatory mediators, such as lipopolysaccharide. 57 Phosphorylation of PFKFB2 or PFKFB3 at equivalent sites near their C-termini increases the synthesis of fructose-2,6-bisphosphate and, hence, promotes glycolysis during hypoxia in heart and in activated monocytes/macrophages, respectively. This may enhance survival of these cells during periods of hypoxia or ischemia.
Although AMPK can, therefore, activate glucose uptake and glycolysis in specific cell types, in the longer term, it tends to promote instead the more glucose-sparing and energy-efficient oxidative metabolism. In skeletal muscle 58, 59 and liver, 60 AMPK activates fatty acid oxidation by inhibiting the ACC1/ ACC2 isoforms of ACC to reduce malonyl-CoA, an inhibitor of the uptake of fatty acids into mitochondria. AMPK promotes the expression of TCA (tricarboxylic acid) cycle enzymes, 61 as well as mitochondrial biogenesis, which it achieves by increasing the expression/activity of the transcriptional co-activator PGC-1α (peroxisome proliferator-activated receptor-gamma co-activator-1 alpha), either by direct phosphorylation triggering a positive feedback effect on its own expression 62 or by enhancing its deacetylation by SIRT1. 63 PGC-1α acts as a co-activator for several transcription factors involved in mitochondrial biogenesis and oxidative metabolism, including myocyte enhancer factor-2, nuclear respiratory factors-1/-2, and PPAR-α and -δ (peroxisome proliferator-activated receptor-alpha and -delta). 64 Despite this evidence that AMPK promotes oxidative metabolism, in mice with a skeletal/cardiac muscle-specific knockout of both AMPK-β subunits, although the mice displayed evidence of dilated cardiomyopathy, the rate of glucose and fatty acid oxidation in hearts perfused under normoxic conditions ex vivo was normal. 65 A final catabolic pathway switched on by AMPK is autophagy, brought about via direct phosphorylation of the protein kinase that triggers that process, ULK1 (Unc-51 like kinase-1). 66 By triggering digestion of cellular contents, autophagy may be critical in enhancing cell survival during periods of acute nutrient starvation, such as during ischemia in cardiac muscle. However, it has also been suggested that excessive autophagy might also contribute to cell damage during ischemia/reperfusion.
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Anabolic Pathways Switched off by AMPK
As well as its classical roles in inhibiting fatty acid and sterol synthesis, 35 AMPK inactivates key enzymes and regulatory proteins involved in triglyceride/phospholipid synthesis, 68 glycogen synthesis, 14, 15 rRNA synthesis, 69 and protein synthesis. The latter is inhibited both at the elongation step by phosphorylation and activation of elongation factor-2 kinase 70 and at the initiation step by inactivation of the mechanistic target-of-rapamycin complex-1 (mTORC1) by multiple mechanisms. 71, 72 By inhibiting mTORC1, AMPK would also be expected to oppose hypertrophy in organs, such as the heart, which in most cases is considered to be a deleterious process.
Role of AMPK in the Heart
Role in the Response to Cardiac Ischemia
It was reported in 1995 that AMPK was activated by no-flow ischemia in perfused rat hearts, an effect associated with high rates of fatty acid oxidation during reperfusion. 73 AMPK is also activated in the heart by increased workload. 74 The role of AMPK in cardiac ischemia has subsequently been addressed using mouse models where AMPK is downregulated or absent. The first was a transgenic model where an inactive AMPK-α2 subunit was expressed in both skeletal and cardiac muscle. By competing with endogenous α subunits for available β and γ subunits, the overexpressed inactive α2 subunit downregulates endogenous α1 and α2 and, thus, acts as a dominant negative mutant. There was no major phenotype under unstressed conditions, but during low-flow ischemia, there was a failure to enhance glucose uptake and glycolysis, while during subsequent reperfusion, there was less fatty acid oxidation, lower ATP levels, and poorer recovery of contractile function. 75 The degree of damage to the myocardium was also greater, suggesting that AMPK exerts a cardioprotective effect overall, even though stimulation of fatty acid oxidation during reperfusion may be deleterious. 73 Using the same model, evidence was obtained that AMPK was required for increased autophagy during ischemia. 76 Next to be studied were conditional knockouts of the upstream kinase LKB1 in both skeletal and cardiac muscle. The basal activity of AMPK-α2 complexes in the heart was completely abolished and did not increase in response to noflow ischemia or anoxia, correlating with a complete lack of ACC phosphorylation at the AMPK site. The AMP:ATP and ADP:ATP ratios were also elevated to a greater extent during no-flow ischemia than in control hearts, confirming that AMPK was protecting the cells against energetic stress. Surprisingly, the activity of AMPK-α1 complexes was almost unaffected by LKB1 knockout and still increased in response to ischemia or anoxia. 77 Broadly, similar results were obtained in studies of perfused hearts from mice with a whole-body knockout of AMPK-α2. 78 Interestingly, left ventricular hypertrophy induced by phenylephrine was greatly accentuated in the hearts from AMPK-α2 knockout mice; this may have been because of less restraint on the mTORC1 pathway because the basal phosphorylation of p70S6K at the mTORC1 site was elevated, although it did not increase further on phenylephrine treatment as in the controls. 79 
Mutations in γ2 and γ3 Subunits Causing Heart Disease and Altered Glycogen Content
The only mutations in any of the 7 genes encoding AMPK subunits clearly shown to cause human pathology are those in PRKAG2, encoding AMPK-γ2. These are associated with multiple cardiac disorders, specifically (1) ventricular preexcitation; (2) excessive glycogen storage in cardiomyocytes; (3) cardiac hypertrophy. Although rare, the PRKAG2 mutations are autosomal dominant in effect and, therefore, occur frequently in affected families. They are invariably missense mutations causing amino acid replacements, of which at least 14 have now been reported ( Table 2 ). The affected residues are perfectly conserved between human γ1, γ2, and γ3 and occur in all 4 CBS repeats. The location of the residues affected in γ2, and of the 3 bound molecules of AMP, are mapped in Figure 3 onto a structure for γ1. 19 Interestingly, 6 of the mutations (R302Q, H383R, R384T, H530R, R531G, and R531Q) affect basic residues whose side chains directly interact with the phosphate groups of ≥1 molecules of AMP or ATP, while 2 others also interact either directly (S548) or indirectly (T400) with AMP. 19 Other affected residues lie in more peripheral regions of the γ subunit, and it is less obvious why their replacement should affect function. In the context of bacterially expressed CBS repeats from AMPK-γ2, the R302Q, H383R, T400N, and R531G mutations all reduced the affinity for ATP, as well as AMP, with the severity of the effects increasing in the order R302Q<H383R<T400N<R531G. 17 When expressed in mammalian cells as α1β1γ2 heterotrimers, these mutations also reduced allosteric activation by AMP, with the R531G mutation abolishing AMPK activation completely. 17, 92 The R384T and R531Q mutations were shown later to cause severe effects on AMPK function, similar to or even greater than R531G. 85, 90 In a comparison of the R531G and R531Q mutations expressed as α1β1γ2 heterotrimers in HEK293 (human embryonic kidney-293) cells, these mutations not only abolished allosteric activation by AMP, but also caused significant increases in basal Thr172 phosphorylation and activity. 90 This was particularly clear in cells stably expressing the R531G mutant, when clones could be selected in which the level of expression of the WT and mutant was identical; the R531G mutant consistently had a 2-fold higher basal Thr172 phosphorylation and activity, although, unlike the wild type, it was completely insensitive to further activation by agents that increase cellular AMP/ADP. 34 Some of the mutations, such as R302Q, can cause relatively mild symptoms so that the patients may not present in the clinic until early adulthood. 83 By contrast, patients with the R531G mutation develop severe symptoms during childhood, 89 while the R384T 85 and R531Q 90 mutations were only detected postmortem in neonates who had died within weeks of birth and appeared to be de novo mutations because neither parent was affected. Consistent with the idea that R531G, R531Q, and R384T cause particularly severe forms of the disease, these were the mutations with the largest effects on binding of AMP and ATP to the γ subunit. 17, 85, 90 It is also interesting that R531 and R384 are involved in the binding of AMP or ATP at the critical site, site 3.
What causes the cardiac sequelae of the PRKAG2 mutations? The reduction of AMP binding to the γ subunit causes reduced activation by AMP and is a loss-of-function effect, whereas the reduction of ATP binding may be responsible for the increased basal activity of the R531G and R531Q mutants and is a gain-offunction effect. Because these mutations are dominant, it seems likely that it is the gain-of-function effect, increased basal activity, that causes most of the pathology; the loss-of-function effect may be compensated for by γ1, which is the major isoform expressed in heart, at least in rodents. 93 This is an important conclusion because pharmaceutical companies are developing AMPK activators to combat Type 2 diabetes mellitus, and it suggests that activation of γ2-containing complexes in the heart might have deleterious effects, as seen with these mutations.
Why does increased basal activity of γ2-containing complexes cause these cardiac phenotypes? AMPK is known to promote glucose uptake in cardiac muscle, 75 so increased basal activity would be expected to cause a high basal uptake, even in the absence of a real demand for glucose. There is good evidence for this scenario from studies of transgenic mice overexpressing the N488I mutation in the heart, which develop ventricular preexcitation and cardiac hypertrophy similar to the human disorder. 94 By 50 days of age, they have a 20-fold increase in cardiac glycogen compared with controls, accompanied by higher rates of glucose uptake and glycogen synthesis but lower rates of lactate production, suggesting that increased glucose uptake is being directed into glycogen synthesis rather than glycolysis. Glycogen synthase was also much more highly phosphorylated in the transgenic mice (presumably because of the high basal AMPK activity), but cellular glucose-6-phosphate (an allosteric activator of glycogen synthase that over-rides the effects of phosphorylation) was also elevated >3-fold. Satisfying confirmation of this interpretation came when the N488I mice were crossed with knock-in mice carrying a mutation that renders glycogen synthase insensitive to glucose-6-phosphate. The presence of the glucose-6-phosphate-insensitive glycogen synthase reversed the high glycogen phenotype of the N488I mice and rescued the ventricular preexcitation but not the cardiac hypertrophy, suggesting that the former but not the latter is secondary to increased glycogen content. 95 Supporting the idea that hyperactivation of the mTORC1 pathway was the cause of hypertrophy, mTORC1 Equivalent residues in the sequences of human γ1 and γ3 are shown in the second and third column and the CBS repeat affected in the fourth. V336 and R350 are located in the linker between CBS1 and CBS2.
targets such as p70S6K and 4EBP1 were more highly phosphorylated in the N488I mice, while treatment with rapamycin reduced, without completely preventing, the hypertrophy. Increased mTORC1 in the N488I mice is actually rather counterintuitive because AMPK is normally thought to inhibit that pathway. 71, 72 However, a recent study has suggested that AMPK can activate mTORC1 under certain circumstances by sustaining the supply of amino acids via autophagy. 96 Why does abnormally high glycogen content lead to ventricular preexcitation? During fetal development, the atria and the ventricles become separated by the growth of a fibrous layer called the annulus fibrosis, which ensures that the only electric connection between the 2 chambers is via the atrioventricular node. In N488I mice, the annulus fibrosis appeared to be thin and disrupted in places, and it was suggested that the presence of glycogen-containing vacuoles in myocytes disrupts its formation during fetal development, causing abnormal electric connections between the atria and ventricles. 97 Most mouse studies of γ2 mutations have involved transgenic mice overexpressing the mutations in human γ2. Although these mice do display the key clinical features of the human syndrome, and mice expressing wild-type γ2 from the same promoters were used as controls, they are not perfect models because γ2 is being overexpressed. Recently, 3 knockin mouse models, in which mutations in the mouse gene equivalent to human R302Q, N488I, or R531G are expressed globally, were studied. 98, 99 There was evidence for increased basal AMPK activity in liver or muscle of all 3 strains. The N488I and R531G mice displayed ventricular preexcitation and modest increases in heart weight, which was associated with large increases in glycogen content in hearts of R531G but not the N488I mice. Both N488I and R531G mice displayed resistance to obesity and hepatic steatosis induced by high-fat diet, but unlike the N488I mice, the R531G mice also displayed impaired renal function associated with glycogen accumulation, cyst formation, and inflammation and apoptosis in the kidney, particularly when on a high-fat diet, 99 By contrast, in the R302Q mice, there was no obvious cardiac phenotype, but the homozygotes developed marked obesity as they aged, with smaller effects in heterozygotes. Obesity appeared to be due mainly to increased food intake through enhanced action of ghrelin, whose effects are mediated by AMPK activation via the CaMKK2 pathway in the hypothalamus. 100, 101 The homozygotes were also hypoinsulemic, apparently because of reduced glucose-stimulated insulin secretion from the pancreas. Overall, the phenotypes of these mice with knock-in mutations in the PRKAG2 gene showed surprising variability. Interestingly, heterozygous human carriers of the R302Q mutation, who have a relatively mild cardiac phenotype, also display some evidence of increased obesity, as well as higher fasting glucose and glycated hemoglobin (HbA1c) and lower insulin levels than unaffected siblings. 98 These noncardiac features of the R302Q mutation only became evident after studies of the mouse model.
Finally, all of the residues mutated in AMPK-γ2 are also conserved in γ1 and γ3 (Table 2 ). It is interesting that none of them have yet been reported to be mutated in the human γ1 gene. However, mutations equivalent to R302Q have been found in both pigs and humans in the γ3 isoform, which is predominantly expressed in skeletal muscle. 93 In human muscle, γ3 appears to be present exclusively as the α2β2γ3 complex, which is the only form of AMPK that is activated during exercise. 6 An R200Q mutation (equivalent to R302Q mutation in human γ2) was found to be a relatively common dominantly acting genetic variant in Hampshire pigs and was associated with a high glycogen content in skeletal muscle; although adversely affecting meat quality, it did not cause obvious clinical problems. 102 Interestingly, in a screen of around 1500 humans, an R225W mutation (R225 being the human equivalent of R302) was found in 2 apparently unrelated individuals, once again not associated with any obvious clinical defects; muscles from humans with this mutation had a higher basal AMPK activity, 2-fold higher glycogen content, and lower triglyceride content. 103 In an in vitro study of myotubes from R225W carriers, they had 3-fold higher mitochondrial content and oxidative capacity, and 2-fold higher basal glucose uptake and glycogen synthesis rates than matched controls. The R225W subjects also had a remarkable resistance to fatigue during isometric contractions of the quadriceps, 104 suggesting that this mutation might confer an advantage during endurance exercise because of the high glycogen content.
Role of AMPK in the Vasculature
In addition to the heart, it has become clear that AMPK has an important role in regulating vascular function, with distinct roles in the functions of vascular endothelial cells (ECs), vascular smooth muscle cells (VSMCs), adventitial cells, and vascular immune cells.
Regulation of AMPK in Endothelial and VSMC
AMPK-α1 accounts for the majority of total AMPK activity in ECs, 105 -107 yet specific downregulation of AMPK-α2 still has marked effects. 108, 109 A wide variety of physiological stimuli have been reported to activate endothelial AMPK, including hypoxia, low glucose and shear stress, [110] [111] [112] adiponectin, 113 angiotensin II, and ghrelin. 114, 115 In addition, CaMKK2 mediates AMPK activation by vasoactive molecules, including thrombin, VEGF (vascular endothelial growth factor), sphingosine-1-phosphate, bradykinin, and estrogen, [116] [117] [118] [119] [120] suggesting that any stimulus that increases Ca 2+ in ECs will activate AMPK. Finally, several widely used hypoglycemic (metformin, thiazolidinediones, salicylate, DPP4 inhibitors, and liraglutide) [121] [122] [123] [124] and hypocholesterolemic (statins and fenofibrate) 125, 126 drugs activate AMPK in cultured ECs. Physiological signals that inhibit AMPK in ECs include high nutrient concentrations, [127] [128] [129] yet the mechanisms by which this inhibition of AMPK in ECs occurs are unclear, although increased PP2A (protein phosphatase-2A)-mediated dephosphorylation of AMPK has been proposed. 127 Endothelial AMPK may, therefore, be suppressed by the high levels of nutrients associated with obesity and insulin resistance. As protein kinase C activation is associated with overnutrition, it is interesting that protein kinase C-mediated inhibitory phosphorylation of Ser487 on AMPK-α1 has been recently reported in ECs. 130 Conversely, the first study of AMPK function in ECs demonstrated that AICAR stimulated fatty acid oxidation, 131 and AMPK activation was subsequently found to normalize impaired fatty acid oxidation and insulin signaling because of high glucose. 132 Stimulation of fat oxidation may partly underlie the effect of AMPK to antagonize palmitatemediated endothelial dysfunction, thus, protecting against lipotoxicity.
As with ECs, AMPK-α1 accounts for the majority of AMPK activity in murine and human VSMCs, 133, 134 and low glucose, adiponectin, estradiol, and metformin all activate AMPK. [135] [136] [137] [138] Angiotensin II has also been reported to acutely activate AMPK, 139 although prolonged activation had no effect. 140 Similar to ECs, high glucose inhibits AMPK in VSMCs, and IGF-1 (insulin-like growth factor-1) also inhibits AMPK, most likely via inhibitory phosphorylation of AMPK-α1 by Akt. 141 Several studies have demonstrated that culture in phosphate/β-glycerophosphate, used to examine VSMC calcification as described later, also inhibits AMPK.
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AMPK and Endothelial Nitric Oxide Synthesis
Endothelium-derived nitric oxide (NO) is a key regulator of vascular function, stimulating VSMC relaxation while inhibiting proinflammatory signaling, leukocyte adhesion, platelet aggregation, VSMC proliferation, and migration associated with pathological vascular remodeling and atherosclerosis. 144 The first indication of a specific vascular role for AMPK came when AMPK was shown to phosphorylate at Ser1177 and activate endothelial NO synthase (eNOS), both in cell-free assays and in ECs. 105, 145 Multiple mechanisms regulate eNOS activity, including Ca 2+ /calmodulin binding, allosteric and protein:protein interactions, cofactor and substrate availability, phosphorylation, and subcellular localization. 144 In addition to Ser1177, AMPK phosphorylates eNOS at Ser633, required for AICAR-stimulated NO synthesis in HEK293 cells. 146 NO synthesis requires dimerization of eNOS and sufficient tetrahydrobiopterin, in whose absence eNOS generates superoxide instead. 144 Another mechanism by which AMPK improves NO synthesis may be by enhancing tetrahydrobiopterin levels because AMPK prevents degradation of GTP cyclohydrolase I, which is the rate-limiting enzyme in tetrahydrobiopterin synthesis. 147 AMPK can, therefore, act by multiple mechanisms to stimulate NO production (Figure 4) , although endothelial AMPK activation is not always associated with eNOS phosphorylation or NO synthesis. 106, 148 AMPK may also mediate some of the endothelial effects of NO because NO donors activate AMPK in ECs. 108 
Endothelial AMPK and Reactive Oxygen Species
Inappropriate levels of reactive oxygen species (ROS), in particular, superoxide anions generated in response to high concentrations of glucose, lipids, and proinflammatory cytokines by NAD(P)H oxidase (Nox), uncoupled eNOS, or mitochondrial respiratory chain complexes, have been implicated in vascular disease. 109, 147, 149, 150 Superoxide reacts with NO to form peroxynitrite, reducing NO bioavailability. 144 AMPK activation in ECs has been widely demonstrated to inhibit ROS formation, increase antioxidant defenses, and promote mitochondrial biogenesis. Downregulation of AMPK in ECs increased activity and expression of Nox, 109 whereas AMPK-dependent inhibition of Nox1/2 translocation to the plasma membrane has also been reported. 121 The mechanism by which AMPK inhibits Nox remains unclear, but may be secondary to reduced protein kinase C-mediated Nox activation or nuclear factor κB (NFκB)-mediated Nox transcription. 109, 121 AMPK-dependent inhibition of mitochondrial ROS formation has also been reported in ECs maintained in high glucose, 149 whereas AMPK-mediated stimulation of tetrahydrobiopterin synthesis, as described earlier, prevents uncoupling of eNOS and superoxide formation. 147 Several groups have reported that AMPK-mediated inhibition of ROS in ECs is associated with increased levels of the antioxidant enzymes superoxide dismutase-2, catalase, and thioredoxin. 149, 151, 152 In ECs, AMPK activation reduces endoplasmic reticulum stress, 153 which is tightly linked to oxidative stress and inflammation, whereas silencing of AMPK increases markers of endoplasmic reticulum stress. 107 Taken together, AMPK activation acts via multiple mechanisms to suppress chronic ROS synthesis in ECs, limiting their damaging actions, as well as the sequestration of NO (Figure 4 ).
AMPK and Vascular Cell Inflammation
The development of endothelial dysfunction and cardiovascular diseases is associated with elevated tumor necrosis factor-α, interleukin (IL)-1β, and IL-6. 154 Tumor necrosis factor-α and IL-1β stimulate activation of NFκB and the Jun N-terminal kinase (JNK) pathway, while IL-6 signals via Janus kinases, leading to phosphorylation of STAT (signal transducer and activation of transcription) proteins. 155 The anti-inflammatory actions of AMPK in ECs were first described when AMPK activation was shown to suppress palmitate-or tumor necrosis factor-α-stimulated NFκB activity. 129 Under basal conditions, NFκB is in an inactive form in the cytoplasm because of binding to IκB (inhibitor of NFkappa B), whereas after cytokine stimulation, IκB phosphorylation by IκB kinase targets it for degradation, allowing NFκB-mediated transcription of proinflammatory cytokines, adhesion molecules, and chemokines. 155, 156 NO inhibits endothelial NFκB activity, 157 suggesting that AMPK-stimulated NO synthesis would inhibit NFκB, although NO donors do not effectively suppress NFκB in ECs with reduced AMPK activity. 108 AMPK-α2 has been reported to phosphorylate IκB kinase β in vitro, inhibiting IκB phosphorylation and NFκB activation, with reduced IL-1β-stimulated IκB kinase phosphorylation observed in ECs lacking AMPK-α2 but not AMPK-α1. 108 Alternatively, AMPK-mediated phosphorylation of the transcriptional co-activator p300 has been proposed to block acetylation and DNA binding by the p65 subunit of NFκB. 158 The idea that AMPK inhibits NFκB signaling is reinforced by functional studies, demonstrating AMPK-dependent inhibition of NFκB-regulated expression of adhesion molecules and MCP-1 (monocyte chemoattractant protein-1). 108, 156 Fewer studies have investigated the effect of AMPK on proinflammatory JNK and IL-6 signaling, although AICAR and metformin reduce JNK activity in ECs, 159 and increased JNK phosphorylation has been reported in ECs lacking AMPK-α2. 107 The mechanism of JNK inhibition is uncertain, although AMPK-dependent inhibition of the upstream kinase MKK4 (dual specificity mitogen-activated protein kinase kinase-4) has been reported in other cells. 160 Recently, AMPK-dependent inhibition of IL-6-stimulated Janus kinase-STAT signaling has been demonstrated in ECs, potentially via direct inhibitory phosphorylation of Janus kinase-1 by AMPK. 122 AMPK activation, therefore, seems to rapidly suppress multiple proinflammatory signaling pathways in ECs by diverse mechanisms. AMPK activation in VSMCs inhibits tumor necrosis factor-α-stimulated NFκB activity and angiotensin IIstimulated STAT1 activity, as well as reducing expression of 2+ levels in VSMCs, reported to be mediated by reduced RhoA activity and increased sarco/endoplasmic Ca 2+ ATPase (SERCA) activity, respectively. AMPK activation in ECs stimulates proliferation and migration, whereas in VSMCs, proliferation and migration are inhibited, associated with p53 phosphorylation, Rb dephosphorylation, and p27 (Kip1) stabilization. AMPK also inhibits VSMC calcification by reducing Runx2 and proinflammatory signaling pathways, leading to leukocyte adhesion and cytokine/chemokine synthesis. IL indicates interleukin; and NFκB, nuclear factor κB. May 26, 2017 inducible NOS and cyclooxygenase-2, and secretion of IL-6 and MCP-1. 161, 162 Thus, AMPK has anti-inflammatory effects in VSMCs, as well as ECs.
AMPK and Angiogenesis
Hypoxia, VEGF, and adiponectin all stimulate AMPKdependent EC migration, although there are conflicting reports as to whether this is mediated by NO. 106, 110, 113, 117, 120 Conversely, downregulation of AMPK attenuates angiogenesis caused by hypoxia, adiponectin, VEGF, or statins, in either tube formation or matrigel plug assays. 106, 110, 113, 125 Mechanistically, increased UCP2 (uncoupling protein-2) or superoxide dismutase-2 have been reported to increase angiogenesis in AMPK-deficient ECs, 163, 164 indicating that downregulation of ROS may be critical. AMPK activation also stimulates VEGF expression, indicating that AMPK positively influences angiogenesis both by increasing VEGF levels and by increasing VEGF signaling. 165 As angiogenesis would also consume significant amounts of ATP, AMPK activation might also serve a permissive role, ensuring adequate generation of ATP to permit EC migration and proliferation.
AMPK and VSMC Contraction
AMPK has direct anticontractile effects on VSMCs because AICAR relaxes aortic rings in an NO-and endothelium-independent manner, an effect lost in AMPK-α1 knockouts. 133 Furthermore, AMPK activation has been reported to affect VSMC contractile signaling, including dephosphorylation of myosin light chain or myosin phosphatase targeting subunit 1. 137, 166 Mechanistically, myosin light chain/myosin phosphatase targeting subunit 1 dephosphorylation may be a consequence of AMPK-mediated inhibition and phosphorylation of RhoA at Ser188, causing subsequent inhibition of ROCK (Rho-associated protein kinase). 137 A769662 has also been reported to reduce intracellular Ca 2+ in VSMCs by increasing sarco/endoplasmic Ca 2+ ATPase activity, associated with increased phosphorylation of phospholamban on Thr17, which disinhibits sarco/endoplasmic Ca 2+ ATPase and, thereby, may underlie sarco/endoplasmic Ca 2+ ATPase activation and vessel relaxation.
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AMPK and Proliferation, Differentiation, and Migration of VSMCs
Unlike ECs, where AMPK upregulates proliferation and migration, thus, supporting angiogenesis, in VSMCs, AMPK inhibits proliferation in response to angiotensin II, PDGF (platelet-derived growth factor), and fetal calf serum, associated with stimulation of p53 Ser15 phosphorylation and reduced Rb phosphorylation. 140, 168 VSMCs from mice lacking AMPK-α2 exhibit increased proliferation, an effect mediated by increased degradation of the cyclin-dependent kinase inhibitor p27
Kip1 triggered by the ubiquitin E3-ligase Skp2. 134 VSMCs retain significant plasticity in vivo and can exhibit a synthetic, proliferative phenotype rather than the quiescent, contractile phenotype observed during atherogenesis. AMPK not only suppresses VSMC proliferation but also inhibits migration and maintains a procontractile phenotype. 169, 170 Inhibition of migration and proliferation are likely to be linked because increased migration of VSMCs lacking AMPK-α2 is reported to be Skp2-dependent. 170 Furthermore, AICAR limits neointima formation after wire injury of rat femoral arteries, which is likely to reflect the antiproliferative, antimigratory actions of AMPK on VSMCs.
139
AMPK and VSMC Calcification
As mentioned earlier, culture in high phosphate/β-glycerophosphate concentrations is used experimentally to stimulate calcium deposition in VSMCs. In vivo, such vascular calcification is frequently associated with ageing, atherosclerosis, and diabetes mellitus. AICAR, adiponectin, and metformin all inhibit VSMC calcification in vitro. 142, 143, 171 In recent studies of atherosclerosis-prone ApoE −/− mice, deletion of AMPK-α1 but not AMPK-α2 caused greater calcification of atherogenic plaques and levels of the osteogenic transcription factor Runx2. 171 Furthermore, metformin reduced atherosclerotic calcification and Runx2 expression in the mice, an effect that was absent in ApoE −/− mice lacking AMPK-α1. The authors of that study further demonstrated that VSMCspecific AMPK-α1 deletion in ApoE −/− mice phenocopied the increased calcification and Runx2 expression, whereas macrophage-specific AMPK-α1 deletion had no effect. The mechanism underlying the AMPK-mediated inhibition of Runx2 levels was further proposed to be mediated by phosphorylation of PIAS1 (protein inhibitor of activated STAT-1) at Ser510, which acts as a SUMO (small ubiquitin-like modifier) E3-ligase to trigger Runx2 SUMOylation and degradation. 171 
Role of AMPK in the Vasculature in Vivo
As many of the actions of AMPK in ECs and VSMCs should have beneficial effects on vascular function ( Figure 5 ), considerable efforts have been made to examine whether AMPK influences vascular tone, remodeling, and atherogenesis in vivo. Under physiological conditions, vascular AMPK has been reported to be activated in vivo by exercise 172 and estradiol 137 and is suppressed by high fat and fructose diets in rodents. 173, 174 Furthermore, exercise stimulates aortic AMPK phosphorylation in both ECs and VSMCs as assessed by immunohistochemistry.
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AMPK and Vascular Tone
As described earlier, AMPK can stimulate NO synthesis by ECs and independently inhibit contractile protein function in VSMCs in vitro. In intact arterial vessels, AICAR stimulates vasodilation in a diverse range of vascular beds from several species, 133, [175] [176] [177] [178] an effect greatly attenuated in mice lacking AMPK-α1. 133 The mechanism of AICAR-stimulated vasodilation remains uncertain and has been variously reported to be endothelium-and NO-dependent, 175, 178 partially NO-and endothelium-dependent 176, 177 or NO-and endothelium-independent. 133 Using endothelium-specific knockouts, it has been proposed that AMPK-α1 is important for endotheliumdependent hyperpolarization-mediated relaxation of resistance arteries. 179 Interestingly, resistance arteries exhibited endothelium-independent dilation in response to A769662, 167 suggesting a VSMC-mediated effect. It is possible that ECs and VSMCs exhibit differential sensitivities to AICAR and A769662 or that some of these may be AMPK-independent effects. Despite studies indicating that AMPK-α2 has a less important role in regulation of vascular tone, 133 ,179 AMPK-α2 knockout mice are hypertensive and exhibit increased contractile responses to phenylephrine in aortic rings. 180 Furthermore, impaired bradykinin-dependent vasodilation has been described in ECspecific AMPK-α2 knockout mice, thought to be because of increased bradykinin degradation by angiotensin-converting enzyme activity. 181 AICAR rapidly reduced blood pressure in spontaneously hypertensive rats, but was without effect in normotensive controls, 176 while prolonged administration of AICAR reduced systolic blood pressure in obese Zucker rats. 182 These data support a role for AMPK in the regulation of vascular tone in disease models, but cannot exclude systemic actions on the heart, kidney, or other tissues. Surprisingly, whether systemic administration of more selective AMPK activators, such as A769662, 991, or C13, alters vascular tone has yet to be reported. More recently, it has become clear that perivascular adipose tissue, which is removed in most myography protocols, has a paracrine anticontractile effect on the underlying vessel. AMPK activity in resistance arteries has been shown to alter the influence of perivascular adipose tissue-derived mediators, 183 and the anticontractile action of perivascular adipose tissue is absent in mice lacking AMPK-α1, perhaps because of reduced adiponectin secretion. 184 AMPK in ECs, VSMCs, and adventitial perivascular adipose tissue may, therefore, all contribute to the maintenance of vascular tone, but the cell type that mediates actions of AMPK on vascular tone may change, depending on the location of the vessel.
AMPK and Atherosclerosis
The potential antiatherogenic actions of AMPK have been investigated in vascular injury models and atherosclerosis-prone hypercholesterolemic mice. AICAR attenuates postischemic leukocyte rolling and adhesion to the endothelium in vivo, an effect lost in AMPK-α1 or AMPK-α2 knockout mice, 185 and systemic administration of AICAR or metformin reduces atherosclerotic lesion size, macrophage accumulation, and inflammation. [186] [187] [188] Similarly, berberine reduced the severity of atherosclerotic lesions in atherosclerosis-prone mice, an effect attenuated in AMPK-α2 knockouts.
189 AMPKα2-deficient mice also exhibited increased atherosclerosis, 107 although the global deficiency makes it difficult to assess whether this was because of a direct effect on vascular tissues. With respect to plaque stability and progression, recent studies have yielded exciting results. Metformin reduced plaque calcification, and mice with a SMC-specific knockout of AMPK-α1 had exacerbated calcification of atherosclerotic plaques in brachiocephalic arteries, phenocopying the increased calcification observed in global AMPK-α1 but not AMPK-α2 knockouts. 171 As the clinical use of metformin is associated with reduced macrovascular morbidity and mortality independently of glycemia, 190 these results may help to define the pathways involved. Using a ligation model for studying injury-induced neointima stability in brachiocephalic arteries, mice with deletion of AMPK-α1 but not AMPK-α2 exhibited more occlusive lesions, with lower collagen and higher macrophage content, indicative of plaque instability. 191 Similarly, in a high-fat diet model, SMC-specific AMPK-α2 knockouts exhibited features of unstable plaques, including phenotype switching of VSMCs. 169 These data, therefore, indicate that AMPK activation may not only inhibit atherogenesis but also inhibit the generation of vulnerable, calcified plaques. Repair of damaged endothelium is also considered important to prevent endothelial dysfunction after injury, and EC-specific expression of constitutively active AMPK has also been reported to promote reendothelialization in a wire injury model, attributable in part to increased mobilization and incorporation of endothelial progenitor cells. 192 Immune cells are involved in all stages of atherosclerosis, and AMPK suppresses inflammatory signaling, monocyte-to-macrophage differentiation, and foam cell formation. 186, 188, 193 Indeed, myeloid-specific AMPK-α1 knockout mice fed an atherogenic diet on a low-density lipoprotein receptor knockout background have recently been shown to exhibit exacerbated atherosclerosis, with increased plaque macrophage content and inflammatory gene expression. 193 All of these studies suggest that AMPK activation limits atherosclerosis, although all of the results are from rodent models, rather than humans. One intriguing question is how, despite only contributing a small fraction of total AMPK activity in vascular cells, specific downregulation of AMPK-α2 has such marked effects on atheroma development in mice, 107, 169, 185, 189 similar to the specific effects noted with respect to vascular tone. 180, 181 It remains to be determined whether there are isoform-specific substrates or specific subcellular localizations that contribute to the vascular function of AMPK-α2.
AMPK and Pulmonary Vascular Remodeling
Several studies have identified a critical role for AMPK in the pulmonary vascular remodeling and perivascular inflammation that characterizes pulmonary arterial hypertension (PAH). Metformin reduces pulmonary artery VSMC proliferation in an AMPK-dependent manner 194 and inhibits the vascular remodeling of pulmonary arteries in rodent models of PAH. 195, 196 Mice with an EC-specific lack of AMPK also exhibit accelerated pulmonary remodeling. 196 Whether the beneficial action of metformin in PAH is mediated by AMPK remains to be determined. By contrast, AMPK activation by hypoxia may contribute to the development of PAH by promoting pulmonary VSMC survival, 197 while AMPK-mediated inhibition of the voltage-gated K + channel Kv1.5 may underlie the acute detrimental effects of hypoxia on PAH.
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Conclusions and Perspectives
AMPK exists as heterotrimeric complexes consisting of catalytic α subunits and regulatory β and γ subunits. AMPK complexes sense the energy status of cells by sensing increases in the cellular AMP:ATP and ADP:ATP ratios. AMP, ADP, and ATP bind at ≤3 sites on the γ subunits; binding of AMP or ADP causes activation by promoting net phosphorylation at Thr172 within the activation loop on the α subunit, while binding of AMP only causes further allosteric activation. Once activated by energy stress, AMPK switches on catabolic pathways that generate ATP, while switching off cell growth and proliferation and other processes that consume ATP.
AMPK seems to exert a protective effect in rodent heart during ischemic episodes. Inherited or de novo mutations in the PRKAG2 gene (encoding AMPK-γ2) in humans cause heart disease of varying severity characterized by ventricular preexcitation, excessive cardiac glycogen content, and hypertrophy. The mutations cause an increase in basal AMPK activity, leading to increased glucose uptake that accounts for the first 2 abnormalities. They also cause a failure of γ2-containing complexes to be further activated by AMP, which might explain the hypertrophy through unrestrained activity of the mTORC1 pathway.
In blood vessels, AMPK inactivation is associated with anticontractile, anti-inflammatory, and antiatherogenic actions on both the vascular endothelium and smooth muscle. Exciting recent studies link AMPK activation to increased stability and reduced calcification of atherosclerotic plaques, as well as highlighting a potential role for AMPK in PAH. Given the critical role of AMPK in the regulation of nutrient metabolism, therapies that activate AMPK may not only normalize metabolic dysfunction but also reduce the burden of cardiovascular complications in obesity and type 2 diabetes mellitus. Recent studies using vascular tissue-specific deletion of AMPK-α isoforms are beginning to elucidate specific roles for AMPK-α isoforms, yet despite the wealth of research demonstrating the functional cardiovascular consequences of AMPK activation, the AMPK substrates involved and underlying mechanisms in several cases remain poorly defined. Emerging technologies such as phosphoproteomics may prove beneficial in understanding such mechanisms after AMPK upregulation or downregulation in cardiovascular tissues in different disease settings and disease models.
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